Silvana Novelli

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

H. Miles Prince, Youn H. Kim, Reinhard Dummer et al. · The Lancet · 2017 · 569 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +9

MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

Alexandra Valera, Armando López‐Guillermo, Teresa M. Cardesa‐Salzmann et al. · Haematologica · 2013 · 225 citations · Full text

Immunology, Pathology, Myc Amplifications +16

<scp>CXCR4</scp> expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival

Marı́a Moreno, Rosa Bosch, Rebeca Dieguez‐Gonzalez et al. · The Journal of Pathology · 2014 · 89 citations

Validation of the <scp>NCCN</scp>‐<scp>IPI</scp> for diffuse large B‐cell lymphoma (<scp>DLBCL</scp>): the addition of β₂‐microglobulin yields a more accurate <scp>GELTAMO</scp>‐<scp>IPI</scp>

Carlos Montalbán, Antonio Díaz‐López, Iván Dlouhy et al. · British Journal of Haematology · 2017 · 81 citations · Full text

Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group

Sara Alonso, Laura Magnano, Miguel Alcoceba et al. · British Journal of Haematology · 2017 · 76 citations · Full text